Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-722782
Tanespimycin · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Tanespimycin + Bortezomib |
| Arm B | ACTIVE_COMPARATOR | Bortezomib |
| tanespimycin and bortezomib | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin. |
| bortezomib and tanespimycin | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin. |
| bortezomib tanespimycin | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin. |
| A1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Tanespimycin | DRUG | Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion |
| Bortezomib | DRUG | Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus |
Inclusion Criteria: * Good Performance Status * Documented evidence of multiple myeloma * Documented progression of disease after initial response to one line of therapy * Measurable disease (serum M-protein \>.5g/dl or \> 200 mg urinary M protein excretion) Exclusion Criteria: * Prior treatment ...
Top 20 of 25 competitors
Tanespimycin is an investigational oncology drug studied in advanced malignancies, multiple myeloma, and solid tumors. It has been evaluated in patients with relapsed or refractory multiple myeloma and in solid tumors, including HER2 positive metastatic breast cancer that had previously failed trastuzumab. It is not an approved therapy.
Tanespimycin targets HSP90AA1 and HSP90AB1, the alpha and beta isoforms of heat shock protein 90. It acts as an HSP90 inhibitor. By binding these chaperone proteins, tanespimycin interferes with the folding and stability of client proteins that cancer cells depend on for growth and survival.
Tanespimycin was developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. The compound is also known by the code KOS-953, reflecting its earlier development history before Bristol-Myers Squibb advanced it in oncology clinical programs.
Tanespimycin is an investigational agent that has been studied in Phase 1, Phase 2, and Phase 3 clinical trials. It is not FDA approved. The completed studies enrolled a total of 53 patients across advanced malignancies, multiple myeloma, and solid tumors, and no trials are currently active.
Completed tanespimycin trials include NCT00546780, a Phase 3 study in multiple myeloma in first relapse, and NCT00514371, a Phase 2 study in relapsed-refractory multiple myeloma. NCT00773344 tested tanespimycin with trastuzumab in solid tumors and HER2 positive metastatic breast cancer, and NCT00779428 was a Phase 2 continuing-treatment study in advanced malignancies.
Yes. Tanespimycin and KOS-953 refer to the same investigational compound. KOS-953 was the earlier development code used in trial titles such as the Phase 3 multiple myeloma study and the Phase 2 relapsed-refractory multiple myeloma study. Both names identify the same HSP90 inhibitor developed by Bristol-Myers Squibb.